Mantle Cell Lymphoma (MCL): Symptoms, Diagnosis, Staging, and Treatment Overview
Mantle Cell Lymphoma (MCL) is a distinct, aggressive B-cell non-Hodgkin lymphoma (5–7% of NHL) characterized by the t(11;14)(q13;q32) translocation causing cyclin D1 overexpression. Median age ~65–70; male predominance (~2:1).
Clinical Presentation
- Generalized lymphadenopathy (cervical, axillary, inguinal)
- B symptoms: Fever, drenching night sweats, >10% weight loss
- Extranodal involvement: GI tract (lymphomatous polyposis), Waldeyer's ring, bone marrow, spleen, liver
- Leukemic phase: Circulating lymphoma cells (often mistaken for CLL)
- Constitutional: Fatigue, early satiety (splenomegaly), abdominal discomfort
Diagnostic Workup
- Excisional lymph node biopsy: Architecture + IHC (CD5+, CD20+, Cyclin D1+, SOX11+)
- FISH/karyotype: Confirm t(11;14); assess complexity (prognostic)
- CT/PET-CT: Staging (Ann Arbor)
- Bone marrow biopsy: Involvement pattern (nodular vs. diffuse)
- Baseline labs: CBC, LDH, β2-microglobulin, renal/hepatic function, viral serologies
- MIPI/MIPI-c: Prognostic indices (age, ECOG, LDH, WBC, Ki-67)
Treatment by Risk/Stage
Early Stage (I–II, Non-Bulky) — Rare
- Radiation therapy ± brief chemoimmunotherapy
Advanced Stage — Fit Patients
- Induction: High-intensity chemoimmunotherapy (R-CHOP, VR-CAP, Nordic MCL2/3, R-HyperCVAD) + rituximab
- Consolidation: Autologous stem cell transplant (ASCT) in first remission — standard for eligible patients
- Maintenance: Rituximab q2–3 months × 2–3 years (prolongs PFS)
Advanced Stage — Unfit/Older Patients
- Bendamustine-rituximab (BR) ± cytarabine
- BTK inhibitor-based regimens (ibrutinib/acalabrutinib/zanubrutinib + rituximab ± venetoclax) — increasing frontline use
- Clinical trials preferred
High-Risk Features (Blastoid/Pleomorphic, TP53 mut, High Ki-67, Complex Karyotype)
- Consider clinical trials, early novel agents, allogeneic transplant in CR1
Prognosis
- Median OS: ~8–10 years (modern era); highly heterogeneous
- 5-year OS: ~65–75% overall; >80% favorable MIPI; <50% high-risk
- Relapse is common; sequential novel agents (BTKi, venetoclax, PI3Ki, CAR-T) extend survival
Specialized lymphoma center care with access to clinical trials optimizes outcomes.
Lymphoma - Related Articles
- Zynlonta (Loncastuximab Tesirine): Antibody-Drug Conjugate Targeting CD19 in B-Cell Lymphoma
- Kleptomania: Compulsive Stealing Disorder Explained
- Mantle Cell Lymphoma Treatment: Understanding Options & Approaches
- Swollen Neck Lymph Nodes: Causes and the Smoking Connection
- Superficial Lymph Nodes: Location, Function, and Metastasis
- Mature vs. Maturing Lymphocytes: Stages of Immune Cell Development
- MALT Lymphoma Causes: Risk and Contributing Factors
